GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biostax Corp (OTCPK:BTAX) » Definitions » ROE %

BTAX (Biostax) ROE % : 0.00% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Biostax ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Biostax's annualized net income for the quarter that ended in Jun. 2024 was $-1.71 Mil. Biostax's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was $-5.08 Mil. Therefore, Biostax's annualized ROE % for the quarter that ended in Jun. 2024 was N/A%.

The historical rank and industry rank for Biostax's ROE % or its related term are showing as below:

During the past 12 years, Biostax's highest ROE % was Negative Equity%. The lowest was -358.36%. And the median was Negative Equity%.

BTAX's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.68
* Ranked among companies with meaningful ROE % only.

Biostax ROE % Historical Data

The historical data trend for Biostax's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biostax ROE % Chart

Biostax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - Negative Equity Negative Equity - -

Biostax Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biostax's ROE %

For the Biotechnology subindustry, Biostax's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biostax's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biostax's ROE % distribution charts can be found below:

* The bar in red indicates where Biostax's ROE % falls into.



Biostax ROE % Calculation

Biostax's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-2.363/( (-2.513+-4.528)/ 2 )
=-2.363/-3.5205
=N/A %

Biostax's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Mar. 2024 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-1.712/( (-4.859+-5.303)/ 2 )
=-1.712/-5.081
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Biostax  (OTCPK:BTAX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-1.712/-5.081
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.712 / 0)*(0 / 0.0065)*(0.0065 / -5.081)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-1.712/-5.081
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1.712 / -1.712) * (-1.712 / -1.2) * (-1.2 / 0) * (0 / 0.0065) * (0.0065 / -5.081)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.4267 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Biostax ROE % Related Terms

Thank you for viewing the detailed overview of Biostax's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biostax Business Description

Traded in Other Exchanges
N/A
Address
2431 Aloma Avenue, Suite 124, Winter Park, FL, USA, 32792
Biostax Corp is a biotechnology company utilizing the Biostax Development Engine, is a developer and marketer of pharmaceutical, biotechnology and MedTech products that have a well-defined path to market. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. It is a therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential.
Executives
Glen A Farmer officer: Chief Financial Officer 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
H. Louis Salomonsky Jr. Revocable Trust 10 percent owner 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Henry Louis Salomonsky director, 10 percent owner 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
Kelly O'brien Wilson 10 percent owner, officer: COO and ICEO and IP 2431 ALOMA AVE, SUITE 124, WINTER PARK FL 32792
James Norman Curley other: Member of 10% owner group 410 DAHLIA AVE, CORONA DEL MAR CA 92625
Empower Insurance Corp Ltd other: Member of 10% owner group 1254 LEEWARD HIGHWAY, 4 CARIBBEAN PLACE, PROVIDENCIALES W7 TKCA1ZZ
Global Reverb Corp 10 percent owner, other: Member of 10% owner group 100 S EOLA DR, UNIT 1703, ORLANDO FL 32801
Paul Puskadi other: Member of 10% owner group 2020 TIGERTAIL BLVD, 7A, DANIA BEACH FL 33004
Deane Rhodes other: Member of 10% owner group 9200 HALSEY CIRCLE NE, TUSCALOOSA AL 35406
Roger Dale Bozarth other: Member of 10% owner group 9028 GREAT HERON CIR, ORLANDO FL 32836
Joel Yanowitz other: Member of 10% owner group 100 TAMAL PLZ, SUITE 106, CORTE MADERA CA 94925
Rogoff Family Trust Dtd other: Member of 10% owner group 20701 N SCOTTSDALE DR, ST 107-501, SCOTTSDALE AZ 85255
George Sasko other: Member of 10% owner group 515 WESTCHESTER DR, STE D, CAMPBELL CA 95008
Raster Investments, Inc other: Member of 10% owner group 2384 ORCHARD CREST BLVD, MANASQUAN NJ 08736
Robert Jackman Dailey other: Member of 10% owner group 401 FIRST STREET, LOS ALTOS CA 94022

Biostax Headlines

From GuruFocus

Immune Therapeutics, Inc. Announces Advisory Board Appointments

By Marketwired Marketwired 10-22-2019